MONOTHERAPY IS PREferred

Size: px
Start display at page:

Download "MONOTHERAPY IS PREferred"

Transcription

1 Monotherapy in Epilepsy Role of the Newer Antiepileptic Drugs Blanca Vazquez, MD NEUROLOGICAL REVIEW Background: Monotherapy is the goal for pharmacological treatment of epilepsy. Well-controlled trials have established the efficacy of some of the newer antiepileptic drugs (AEDs) as monotherapy. Objective: To review clinical data and expert opinions pertinent to the evaluation of most of the newer AEDs as monotherapy for epilepsy. Data Sources: The MEDLINE database was searched for clinical trials using newer AEDs. Reference sections of review articles were manually searched to identify relevant studies not retrieved in MEDLINE. Study Selection: The resulting list of references was manually reviewed to identify monotherapy studies. Results: Lamotrigine and oxcarbazepine demonstrated efficacy in randomized active-control trials in patients with newly diagnosed epilepsy and in substitution trials in patients refractory to conventional AEDs. Conclusion: Lamotrigine and oxcarbazepine are as effective as conventional AEDs at controlling partial seizures and are better tolerated. Arch Neurol. 2004;61: Author Affiliation: Department of Neurology, NYU School of Medicine, New York, NY. MONOTHERAPY IS PREferred when treating epilepsy, although previous reports indicate that polytherapy was sometimes the standard of care and given routinely as initial treatment. 1 Polytherapy began to be questioned shortly after studies showed that 50% to 75% of patients who started on monotherapy remained seizure free for at least 1 year and that monotherapy is equally or more effective, better tolerated, and associated with fewer drug interactions comparedwithpolytherapy. 2-7 Otheradvantages of monotherapy include better compliance, lower costs, and improved quality of life. 1 The efficacy of conventional antiepileptic drugs (AEDs), including phenytoin, carbamazepine, phenobarbital, and valproate, as monotherapy is accepted, 7-10 but efficacy of monotherapy with some of the newer AEDs has been established in wellcontrolled trials. To protect patients from the potential dangers of a noneffective agent used as monotherapy, many newer medications were initially studied as adjunctive therapy in refractory patients, 1 and when efficacy and tolerability as adjunctive treatments were established, newer medications were then studied as monotherapy. 11 However, felbamate and oxcarbazepine were studied as adjunctive therapy and monotherapy simultaneously Sufficient data are now available to establish the efficacy and tolerability of some of the newer AEDs as monotherapy. This article reviews data pertinent to evaluating the role of the newer AEDs, including felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, and topiramate, as monotherapy. EVALUATING MONOTHERAPY CLINICAL TRIALS The long-term, randomized, doubleblind, placebo-controlled clinical trial of monotherapy in epilepsy is generally untenable for new AEDs because of possible harm arising from withholding active treatment. Randomized activecontrol trials comparing monotherapy with a test medication and monotherapy with a reference medication (typically a conventional AED with established efficacy) in newly diagnosed patients are the next best alternative, allowing assessment of efficacy and tolerability under conditions approximating clinical use. 11 Because a new drug would not be expected to surpass the 1361

2 high (70%-80%) seizure remission rates achieved with established agents, demonstration of comparable efficacy of the test and reference medications is interpreted as evidence of the test medication s efficacy. Randomized, double-blind substitution trials gradually transition refractory patients to monotherapy with either a new AED or a conventional AED as the reference medication. 11 As with double-blind, head-to-head monotherapy trials, demonstration of comparable efficacy of the test and reference medications is interpreted as evidence of efficacy of the test medication. While clinicians generally accept comparable efficacy of test and reference medications in double-blind comparator trials as evidence of the test medication s efficacy, regulatory authorities considering whether to approve new medications as monotherapy may not. To be statistically powered to show equivalence between the comparator medications, these trials generally need to include a prohibitively large number of patients. If a study is underpowered, a demonstration of apparent comparable efficacy cannot exclude the possibility that test and reference medications are both ineffective. In this case, a demonstration of superior efficacy of the test medication over the reference medication provides the only incontrovertible evidence of its efficacy. This hurdle is too high for most test AEDs to overcome, although the test drug may be effective as monotherapy in the clinical setting. 11 Several alternative study designs compare test medication with a suboptimal treatment, which may be a nontherapeutic dose of the same drug, a different drug, or a placebo. Presurgical trials compare high doses of a test AED with placebo in patients with refractory seizures who need to discontinue their current therapy for evaluation before epilepsy surgery. 16 These trials are of short duration because of the risks patients are exposed to in the placebo arm (ie, no AED treatment). This trial design compares the seizure frequency between the study drug and placebo, just as in other placebo-controlled trials. In openlabel substitution trials, a high dosage of the test medication is compared with a suboptimal dosage of the same drug or with either a suboptimal drug or an effective dosage of a different one. 11 When ethically feasible, a placebo group sometimes takes the place of the active comparator in substitution trials. These alternative study designs require relatively few patients to demonstrate statistically significant effects of treatment. However, because of short duration and lack of flexibility for titrating doses to optimum levels, the practical relevance of data derived from these studies is limited. A full discussion of all the complexities of monotherapy trial designs is beyond the scope of this article. The reader is encouraged to refer to other reviews for a more complete discussion of trial designs for monotherapy studies in epilepsy. 11,16-18 DATA FROM THE STUDIES Clinical studies of the newer AEDs as monotherapy were identified through searches of the National Library of Medicine s PubMed database, using as key words the names of the newer AEDs (ie, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, and zonisamide) and the term clinical trial. No date limits were applied. The resulting list of references was manually reviewed to identify monotherapy studies. Reference sections of review articles on AEDs were manually searched to identify relevant studies not identified in the PubMed searches. Data presented at professional meetings in abstract form are not included in this review. Because no clinical studies on zonisamide as monotherapy were identified with the methods described above, that agent is not discussed in this review. RANDOMIZED ACTIVE-CONTROL TRIALS Numerous active-control comparisons of new AEDs with conventional medications have been conducted in patients with newly diagnosed epilepsy, and results of several open-label comparisons are also available Three of the studies employed a randomized, open-label design, 23,28,29 1 randomized study had both an open-label and a double-blind component, 19 and the other 7 were randomized, double-blind trials ,24-27 Most of these studies were of sufficient duration (approximately 1 year) to allow assessment of long-term effects of the drugs on seizure control. Furthermore, many of these studies employed flexible dose-titration schedules, allowing investigators to adjust doses. Gabapentin, lamotrigine, oxcarbazepine, and vigabatrin have been compared with conventional AEDs in patients with newly diagnosed epilepsy in randomized activecontrol trials. Except for vigabatrin, which compared with carbamazepine was associated with a higher percentage of discontinuations because of lack of efficacy, 28 the studies show that newer agents are as effective in controlling seizures as reference AEDs including carbamazepine, phenytoin, and valproate. Seizure-free rates with both test and reference AEDs ranged from approximately 40% to 75%, consistent with rates historically observed with conventional AEDs. 2,8-10 One randomized, active-control study compared 2 newer AEDs rather than a newer AED with a conventional one. 20 That study, a randomized, double-blind, flexible-dose comparison of lamotrigine and gabapentin, demonstrated that both drugs were well tolerated and comparably effective in patients with newly diagnosed partial and tonic-clonic seizures, with 76% of patients in each group remaining seizure free for the last 12 weeks of monotherapy. The newer AEDs were nearly always better tolerated, as reflected in lower frequencies of adverse events or lower rates of withdrawal from the study because of adverse events. Gabapentin (1 study), lamotrigine (3 studies), oxcarbazepine (1 study), and vigabatrin (2 studies) were each better tolerated than carbamazepine; oxcarbazepine was better tolerated than phenytoin (2 studies). 19,22-24,26-29 Lamotrigine and oxcarbazepine consistently demonstrate efficacy in randomized active-control trials Furthermore, monotherapy with these drugs is better tolerated than monotherapy with conventional AEDs. Additional study of the other newer AEDs is warranted before definitive conclusions can be drawn about them: 1362

3 gabapentin was effective vs a conventional AED in 1 activecontrol study 19 ; mixed results have been obtained with vigabatrin 28,29 ; and felbamate, levetiracetam, tiagabine, and topiramate have not been assessed in published, randomized active-control studies in patients with newly diagnosed epilepsy. PLACEBO-CONTROLLED TRIAL IN ABSENCE SEIZURES Data from active-control studies are supplemented by a placebo-controlled trial of the efficacy of lamotrigine (median dose, 15 mg/kg per day) for absence seizures in 45 children aged 3 to 15 years with newly diagnosed epilepsy. 30 A placebo control group was feasible because of the relatively benign nature of absence seizures; withholding effective treatment from the placebo group for the brief, 4-week treatment period would not endanger patients because this trial employed an escape design. When patients entered the double-blind phase, their absence seizures were fully controlled. Patients would exit the double-blind arm as soon as they were no longer seizure free. Therefore, the only patients exposed to placebo for 4 weeks were those who remained seizure free. Lamotrigine was significantly more effective than placebo, with 64% of patients receiving lamotrigine monotherapy free of absence seizures during the 4-week doubleblind phase compared with 21% of placebo recipients. Lamotrigine was well tolerated, and no patient withdrew from the study because of adverse events. SUBSTITUTION TRIALS Several double-blind and open-label substitution trials have been conducted with the newer AEDs. 13,31-38 These trials generally enrolled patients with epilepsy refractory to conventional AEDs and were initiated with add-on phases during which patients were introduced to increasing doses of the test AED while their current AED was discontinued. A period of monotherapy with the test drug ensued. Patients with worsening epilepsy (usually measured by an increase in seizure frequency, severity, or the emergence of a new seizure type) or patients who did not tolerate the test AED were withdrawn from the study. Active-control substitution trials were conducted with felbamate (2 studies) and lamotrigine (1 study), both of which were significantly more effective as monotherapy than low-dose or a minimally effective dose of valproate. 13,31,32 In the only long-term, placebocontrolled substitution trial, 3000 mg of levetiracetam was significantly more effective than placebo during 12 weeks of monotherapy. 35 Substitution trials comparing low and high doses of the test AED have been carried out with oxcarbazepine (300 mg/d vs 2400 mg/d), tiagabine (6 mg/d vs 36 mg/d), and topiramate (100 mg/d vs 1000 mg/d) In all comparisons, the high dose of study medication was more effective at controlling seizures or prolonging time in the study. Generally, overall retention rates in these studies are low, and occurrence of adverse effects may be due to the high doses and rapid titration used. Overall, substitution trials are consistent with randomized active-control trials in demonstrating efficacy of newer AEDs. The data for felbamate, lamotrigine, and levetiracetam are most robust because they were obtained from studies using an active comparator or a placebo control group. 13,31,32,35 The other studies, which either were open-label and did not include a comparator or compared low and high doses of the test AED, should be interpreted cautiously because of the lack of a reference treatment. 33,34,36-38 Substitution trials extend the data from the trials in patients with newly diagnosed epilepsy by showing that seizures can be controlled with the newer medications in many patients refractory to conventional AEDs. The findings should be generalized to clinical practice carefully because these treatment-resistant patients may not be representative of typical clinical populations of patients with epilepsy. PRESURGICAL TRIALS Presurgical trials have been conducted with felbamate, gabapentin, oxcarbazepine, and tiagabine. 15,37,39,40 In 3 placebo-controlled studies (felbamate, oxcarbazepine, and tiagabine), the test AED was more effective than placebo at reducing seizure frequency or prolonging time in the study. 15,37,39 In the fourth comparison, a higher daily dose of gabapentin (3600 mg) was more effective than a lower dose (300 mg) in prolonging time in the study. 40 Presurgical trials, while having the benefit of a placebo group, provide limited information because their design does not mimic clinical practice. These trials are of short duration (ie, 8-10 days), the inpatient setting is more controlled (ie, supervised) than an outpatient setting, study medication is administered via unorthodox conditions (ie, with rapid-dose escalation after abrupt withdrawal of the patient s usual AED), and AED doses cannot be titrated as they would be in clinical practice. OTHER FACTORS TO CONSIDER IN EVALUATING MONOTHERAPY Because currently available AEDs are generally not distinguishable on the basis of efficacy data from clinical trials, factors such as mechanism of action, spectrum of activity, neuropsychiatric profile, sedative burden, longterm adverse effects, and ease of dosing need to be considered in choosing AEDs for monotherapy. 6 Many of these features are not directly assessed in clinical trials. Taking into account these features and others, the newer AEDs lamotrigine, gabapentin, oxcarbazepine, and vigabatrin are considered to have better profiles as AED monotherapies than the conventional AEDs phenobarbital, phenytoin, carbamazepine, and valproate. Specific advantages of the newer AEDs include better tolerability, predictable kinetics, and broad-spectrum efficacy or well-defined spectrum of efficacy. In addition to these characteristics of AEDs, medication effects in special patient populations warrant consideration. 6 It is important to be aware that some AEDs (phenobarbital, phenytoin, carbamazepine, oxcarbaz- 1363

4 epine, felbamate, and topiramate) increase the metabolism of hormonal contraceptives, while others (valproic acid, vigabatrin, lamotrigine, gabapentin, tiagabine, and levetiracetam) do not interact with hormonal contraceptives. 41 Drugs with cognitive adverse effects should be avoided in elderly patients, who may be particularly susceptible to central nervous system toxicity. Finally, there is evidence to suggest that the majority of patients who achieve seizure freedom with AEDs do so with monotherapy. The results of a prospective study evaluating AED response in patients with newly diagnosed epilepsy suggest that, regardless of the drug, only a relatively small percentage of patients who do not achieve seizure control with monotherapy will achieve control with polytherapy. Of the 64% of patients naïve to AEDs before the start of the study who became seizure free, 61% achieved seizure freedom with monotherapy, while the remaining 3% were seizure free with a 2-drug regimen. 42 The finding that only 3% of the 64% of patients who were seizure free required polytherapy suggests that, for most patients who are responsive to pharmacotherapy, monotherapy is an effective treatment regimen. Leaders in the field of epilepsy recommend valproate and lamotrigine as first-line monotherapy for generalized tonic-clonic seizures; valproate, ethosuximide, and lamotrigine for absence seizures; and valproate and lamotrigine for myoclonic seizures. Lamotrigine was recommended as first-line treatment for idiopathic generalized epilepsy among women of reproductive age, including those who are pregnant or breastfeeding; elderly patients; and those with intellectual impairment. 43 Oxcarbazepine is currently approved by the Food and Drug Administration as monotherapy for partial seizures in adults, and lamotrigine is Food and Drug Administrationapproved for conversion to monotherapy in adults with partial seizures. COMMENT Long-term, randomized, double-blind, placebocontrolled trials are not appropriate to evaluate monotherapy because of the risks involved in withholding active treatment from a patient. Therefore, several alternative designs are generally used. It is important to keep the strengths and weaknesses of these trial designs in mind when interpreting results and evaluating options for monotherapy. Results of several clinical trials demonstrate that the newer AEDs can be as effective as monotherapy for epilepsy. Efficacy is particularly well established for lamotrigine and oxcarbazepine, and compared with conventional AEDs such as carbamazepine, phenytoin, and valproate, both are equally effective at controlling seizures and are better tolerated. Data for the other newer AEDs are both less voluminous and less consistent than those for lamotrigine and oxcarbazepine, and additional clinical study is warranted before the place of these medications can be established. Accepted for Publication: Feburary 4, Correspondence: Blanca Vazquez, MD, NYU Comprehensive Epilepsy Center, 403 East 34th St, RIV Fourth Floor, New York, NY (blancavs@netscape.net). REFERENCES 1. Guberman A. Monotherapy or polytherapy for epilepsy? Can J Neurol Sci. 1998; 25:S3-S8. 2. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonicclonic seizures. N Engl J Med. 1985;313: Beghi E, Tognoni G. Prognosis of epilepsy in newly referred patients: a multicenter prospective study. Epilepsia. 1988;29: Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia. 1983; 24: Theodore WH, Porter RJ. Removal of sedative-hypnotic antiepileptic drugs from the regimens of patients with intractable epilepsy. Ann Neurol. 1983;13: Brodie MJ. Monostars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia. 1999;40(suppl 76):S17-S Schneiderman JH. Monotherapy versus polytherapy in epilepsy: a framework for patient management. Can J Neurol Sci. 1998;25:S9-S Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia. 1992;33: Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry. 1995; 58: de Silva M, MacArdle B, McGowan M. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet. 1996;347: Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res. 1999;33: Theodore WH, Raubertas RF, Porter RJ, et al. Felbamate: a clinical trial for complex partial seizures. Epilepsia. 1991;32: Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partialonset seizures: an active-control trial. Neurology. 1993;43: Glauser TA, Nigro M, Sachdeo R, et al; Oxcarbazepine Pediatric Study Group. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology. 2000;54: Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control monotherapy trial for partial seizures. Neurology. 1999; 52: Pledger G. Monotherapy trials: presurgical studies. Epilepsy Res. 2001;45: Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology. 2003;60(suppl 4):S2-S Beydoun A, Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory partial seizures. Neurology. 2003;60(suppl 4):S13-S Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology. 1998;51: Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002; 43: Brodie MJ, Overstall PW, Giorgi L; The UK Lamotrigine Elderly Study Group. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 1999; 37: Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995;345: Reunanen M, Dam M, Yuen AWC. A randomised open multicenter comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res. 1996;23: Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3: Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26: Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:

5 27. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27: Kälviäinen R, Äikiä M, Saukkonen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized, controlled study. Arch Neurol. 1995;52: Tanganelli P, Regesta G. Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res. 1996;25: Frank LM, Enlow T, Holmes GL, et al. Lamictal monotherapy for typical absence seizures in children. Epilepsia. 1999;40: Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol. 1992;32: Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology. 1998;51: Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. 1997;26: Jozwiak S, Terczynski A. Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. Seizure. 2000;9: Ben-Menachem E, Falter U ; The European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. 2000;41: Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures. Neurology. 2000;54: Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia. 1995;36(suppl 6):S2-S Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia. 1997;38: Devinsky O, Faught RE, Wilder BJ, et al. Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res. 1995; 20: Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy: an 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology. 1997; 49: Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16: Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342: Karceski S, Morrell M, Carpenter D. The expert consensus guideline series: treatment of epilepsy. Epilepsy Behav. 2001;2(suppl 6):A1-A

Therapeutic strategies in the choice of antiepileptic drugs

Therapeutic strategies in the choice of antiepileptic drugs Acta neurol. belg., 2002, 102, 6-10 Original articles Therapeutic strategies in the choice of antiepileptic drugs V. DE BORCHGRAVE, V. DELVAUX, M. DE TOURCHANINOFF, J.M. DUBRU, S. GHARIANI, Th. GRISAR,

More information

2018 American Academy of Neurology

2018 American Academy of Neurology Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of

More information

Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy

Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy S Venkataraman *, CS Narayanan ** * Senior Consultant Neurologist, Mata Chanan Devi Hospital, New Delhi; ** Classified Specialist (Medicine

More information

Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials

Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials Ahmad Beydoun, M.D. Oxcarbazepine is approved as monotherapy and adjunctive therapy for partial seizures with and without

More information

2018 American Academy of Neurology

2018 American Academy of Neurology Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the

More information

Difficult to treat childhood epilepsy: Lessons from clinical case scenario

Difficult to treat childhood epilepsy: Lessons from clinical case scenario Difficult to treat childhood epilepsy: Lessons from clinical case scenario Surachai Likasitwattanakul, M.D. Department of Pediatrics Faculty of Medicine, Siriraj Hospital Natural history of Epilepsy Untreated

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium

More information

Keywords: treatment; epilepsy; population based cohort Institute of Neurology, University College London, London WC1N 3BG, UK

Keywords: treatment; epilepsy; population based cohort Institute of Neurology, University College London, London WC1N 3BG, UK 632 Institute of Neurology, University College London, London WC1N 3BG, UK S D Lhatoo JWASSander S D Shorvon Correspondence to: Professor J W Sander, Department of Clinical and Experimental Epilepsy, Institute

More information

AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS

AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS Volume 24, Issue 1 October 2008 AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS Jason Richey, Pharm.D. Candidate Epilepsy is a neurological disorder characterized by sudden

More information

Refractory epilepsy: treatment with new antiepileptic drugs

Refractory epilepsy: treatment with new antiepileptic drugs Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department

More information

BIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY

BIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY BIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY Bibliographic Marson AG et al. for (Review). The Cochrane 2000 De Silva M et al. Romised or for childhood. Lancet, 1996; 347: 709-713

More information

PROCEEDINGS PHARMACOLOGIC TREATMENT CONSIDERATIONS * Dennis J. Dlugos, MD ABSTRACT

PROCEEDINGS PHARMACOLOGIC TREATMENT CONSIDERATIONS * Dennis J. Dlugos, MD ABSTRACT PHARMACOLOGIC TREATMENT CONSIDERATIONS * Dennis J. Dlugos, MD ABSTRACT A number of traditional and newer antiepileptic drugs (AEDs) are used for the initial treatment of new-onset epilepsy. The decision-making

More information

The New England Journal of Medicine EARLY IDENTIFICATION OF REFRACTORY EPILEPSY. Patients

The New England Journal of Medicine EARLY IDENTIFICATION OF REFRACTORY EPILEPSY. Patients EARLY IDENTIFICATION OF REFRACTORY EPILEPSY PATRICK KWAN, M.D., AND MARTIN J. BRODIE, M.D. ABSTRACT Background More than 30 percent of patients with epilepsy have inadequate control of seizures with drug

More information

Update in Clinical Guidelines in Epilepsy

Update in Clinical Guidelines in Epilepsy Why We Need Clinical Guidelines? Clinician needs advice! Update in Clinical Guidelines in Epilepsy Charcrin Nabangchang, M.D. Phramongkutklao College of Medicine Tiamkao S, Neurology Asia2013 Why We Need

More information

Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy

Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy Special Article Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee

More information

MONOTHERAPY OR POLYTHERAPY FOR CHILDHOOD EPILEPSIES?

MONOTHERAPY OR POLYTHERAPY FOR CHILDHOOD EPILEPSIES? MONOTHERAPY OR POLYTHERAPY FOR CHILDHOOD EPILEPSIES? Oluwaseun Egunsola 1, Helen M Sammons 1 and William P Whitehouse 2,3 1Academic Division of Child Health, University of Nottingham, Derbyshire Children

More information

Updated advice for nurses who care for patients with epilepsy

Updated advice for nurses who care for patients with epilepsy NICE BULLETIN Updated advice for nurses who care for patients with epilepsy NICE provided the content for this booklet which is independent of any company or product advertised NICE BULLETIN Updated advice

More information

Topiramate in clinical practice: first year s postlicensing experience in a specialist epilepsy clinic

Topiramate in clinical practice: first year s postlicensing experience in a specialist epilepsy clinic J Neurol Neurosurg Psychiatry 1999;66:759 763 759 The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK M W Kellett D F Smith P A Stockton D W Chadwick Correspondence to: Dr

More information

Opinion 24 July 2013

Opinion 24 July 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4

More information

Treatment of epilepsy in adults

Treatment of epilepsy in adults Treatment of epilepsy in adults Review 33 Treatment of epilepsy in adults S B Gunatilake 1, A Arasalingam 2 Sri Lanka Journal of Neurology, 2012, 1, 33-38 Case vignettes 1. A 60-year old patient with long

More information

Intervention [5] Comparison [6]

Intervention [5] Comparison [6] Cowan LD. The epidemiology of the epilepsies in children. Mental Retardation and Developmental Disabilities Res Reviews, 2002; 8: 171-181 Review article Paediatric patients Discusses incidence and prevalence

More information

ORIGINAL CONTRIBUTION

ORIGINAL CONTRIBUTION Epilepsy in Childhood An Audit of Clinical Practice ORIGINAL CONTRIBUTION Hans A. Carpay, MD; Willem F. M. Arts, MD, PhD; Ada T. Geerts, MSc; Hans Stroink, MD; Oebele F. Brouwer, MD, PhD; A. C. Boudewyn

More information

Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre

Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre Original article Epileptic Disord 2012; 14 (4): 379-87 Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre Bernhard J Steinhoff, Anke Maren

More information

TITLE: Pharmacological Treatments in Patients with Epilepsy: Guidelines

TITLE: Pharmacological Treatments in Patients with Epilepsy: Guidelines TITLE: Pharmacological Treatments in Patients with Epilepsy: Guidelines DATE: 01 April 2011 RESEARCH QUESTION What are the evidence-based guidelines for pharmacological treatments in patients with epilepsy?

More information

Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol

Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol Market DC Antiepileptics Override(s) Approval Duration Prior Authorization 1 year Step Therapy Quantity Limit *Indiana Medicaid See State Specific Mandate below *Maryland Medicaid See State Specific Mandate

More information

Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials

Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical

More information

When choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.

When choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E. ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends

More information

Comparative bioethics in bipolar and epilepsy research

Comparative bioethics in bipolar and epilepsy research Seizure 2002; 11: 51 56 doi:10.1053/seiz.2001.0585, available online at http://www.idealibrary.com on Comparative bioethics in bipolar and epilepsy research KENNETH R. KAUFMAN Associate Professor of Psychiatry

More information

TRANSPARENCY COMMITTEE OPINION. 19 July 2006

TRANSPARENCY COMMITTEE OPINION. 19 July 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated

More information

Monotherapy and polytherapy in Paediatric seizures: A prospective, observational study in a tertiary care teaching hospital

Monotherapy and polytherapy in Paediatric seizures: A prospective, observational study in a tertiary care teaching hospital Original Research Article Monotherapy and polytherapy in Paediatric seizures: A prospective, observational study in a tertiary care teaching hospital Henry Daniel Raj T 1, Sylvia A 2*, Chidambaranathan

More information

AED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology

AED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology AED Treatment Approaches David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology Audience Response Keypads Please utilize the keypad at your table to answer questions throughout

More information

Tailoring therapy to optimize care for Epilepsy. Dr Tim Wehner National Hospital for Neurology and Neurosurgery London, UK For discussion only

Tailoring therapy to optimize care for Epilepsy. Dr Tim Wehner National Hospital for Neurology and Neurosurgery London, UK For discussion only Tailoring therapy to optimize care for Epilepsy Dr Tim Wehner National Hospital for Neurology and Neurosurgery London, UK For discussion only Disclosures Session (travel expenses) sponsored by Pfizer Premature

More information

Optimizing Antiepileptic Drug Therapy in Refractory Epilepsy

Optimizing Antiepileptic Drug Therapy in Refractory Epilepsy 15 Optimizing Antiepileptic Drug Therapy in Refractory Epilepsy Nicholas P. Poolos Department of Neurology and UW Regional Epilepsy Center, University of Washington, Seattle, WA, USA Introduction: When

More information

Topics. A. Simple partial seizures

Topics. A. Simple partial seizures Management of Partial Epilepsy: Focus on Sodium Valproate Asia Pacific Epilepsy Meeting 8 Associate Professor Somsak Tiamkao Division of Neurology, Department of Medicine Srinagarind Epilepsy Research

More information

New Medicines Profile

New Medicines Profile New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)

More information

Prescribing and Monitoring Anti-Epileptic Drugs

Prescribing and Monitoring Anti-Epileptic Drugs Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University

More information

eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd

eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

Newer antiepileptic drugs and recent advances in drug therapy of epilepsy

Newer antiepileptic drugs and recent advances in drug therapy of epilepsy Newer antiepileptic drugs and recent advances in drug therapy of epilepsy Torbjörn Tomson Department of Neurology, Karolinska Hospital, S 171 76, Stockholm, Sweden Nine new antiepileptic drugs (AEDs) have

More information

PEDIATRIC PHARMACOTHERAPY

PEDIATRIC PHARMACOTHERAPY PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the Children s Medical Center at the University of Virginia Volume 7 Number 11 November 2001 A Oxcarbazepine Use in Children

More information

Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options

Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options Seizure 1995: 4:37-44 Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options B.A. O'NEILL, M.R. TRIMBLE* & D.S. BLOOM Arthur D. Little Ltd, Berkley Square House,

More information

Zonisamide Should Be Considered a First-Line Antiepileptic Drug for Patients with Newly Diagnosed Partial Epilepsy

Zonisamide Should Be Considered a First-Line Antiepileptic Drug for Patients with Newly Diagnosed Partial Epilepsy Current Literature In Clinical Science Zonisamide Should Be Considered a First-Line Antiepileptic Drug for Patients with Newly Diagnosed Partial Epilepsy Efficacy and Tolerability of Zonisamide Versus

More information

CLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice?

CLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice? FROM CLINICAL TRIALS TO CLINICAL PRACTICE: TRANSLATING EPILEPSY RESEARCH INTO PATIENT CARE Interview with Jacqueline A. French, MD Dr Jacqueline A. French is a Professor in the Department of Neurology

More information

When to start, which drugs and when to stop

When to start, which drugs and when to stop When to start, which drugs and when to stop Dr. Suthida Yenjun, MD. PMK Epilepsy Annual Meeting 2016 The main factors to consider in making the decision The risk for recurrent seizures, which varies based

More information

levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd

levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines

More information

Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy

Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy Special Article CME Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee

More information

Epilepsy: problems of diagnosis and recommended treatment Nicola Cooper MRCP and Morgan Feely MD, FRCP, FRCP(I)

Epilepsy: problems of diagnosis and recommended treatment Nicola Cooper MRCP and Morgan Feely MD, FRCP, FRCP(I) Epilepsy: problems of diagnosis and recommended treatment Nicola Cooper MRCP and Morgan Feely MD, FRCP, FRCP(I) VM Our series Prescribing in gives practical advice for successful management of the special

More information

Epilepsia, 45(5): , 2004 Blackwell Publishing, Inc. C 2004 International League Against Epilepsy. C 2004 AAN Enterprises, Inc.

Epilepsia, 45(5): , 2004 Blackwell Publishing, Inc. C 2004 International League Against Epilepsy. C 2004 AAN Enterprises, Inc. Epilepsia, 45(5):410 423, 2004 Blackwell Publishing, Inc. C 2004 International League Against Epilepsy C 2004 AAN Enterprises, Inc. Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment

More information

Ernie Somerville Prince of Wales Hospital EPILEPSY

Ernie Somerville Prince of Wales Hospital EPILEPSY Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist

More information

WHY CHILDREN ARE DIFFERENT FROM ADULTS

WHY CHILDREN ARE DIFFERENT FROM ADULTS XXASIM May p159-165 5/14/01 9:23 AM Page 159 NEW PHARMACOLOGICAL TREATMENTS FOR PEDIATRIC EPILEPSY Blaise F.D. Bourgeois, MD KEY POINTS Antiepileptic drugs (AEDs) are tailored to pediatric epilepsy seizure

More information

APPENDIX S. Removed sections from original guideline. 1.1 Pharmacological treatment Introduction

APPENDIX S. Removed sections from original guideline. 1.1 Pharmacological treatment Introduction 00 0 APPENDIX S Removed sections from original guideline. Pharmacological treatment.. Introduction The evidence base for the newer AEDs (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine,

More information

Children Are Not Just Small Adults Choosing AEDs in Children

Children Are Not Just Small Adults Choosing AEDs in Children Children Are Not Just Small Adults Choosing AEDs in Children Natrujee Wiwattanadittakun, MD Neurology division, Department of Pediatrics, Chiang Mai University Hospital, Chiang Mai University 20 th July,

More information

Introduction to seizures and epilepsy

Introduction to seizures and epilepsy Introduction to seizures and epilepsy Selim R. Benbadis, M.D. Professor Departments of Neurology & Neurosurgery Director, Comprehensive Epilepsy Program Symptomatic seizures Head injury (trauma) Stroke

More information

Clinical Trials for Treatment of Primary Generalized Epilepsies

Clinical Trials for Treatment of Primary Generalized Epilepsies Epilepsia, 44(Suppl. 7):44 50, 2003 Blackwell Publishing, Inc. C International League Against Epilepsy Clinical Trials for Treatment of Primary Generalized Epilepsies Edward Faught University of Alabama

More information

New drug treatments for epilepsy

New drug treatments for epilepsy J Neurol Neurosurg Psychiatry 2001;70:143 148 143 EDITORIAL New drug treatments for epilepsy After the introduction of valproate in 1973, excluding benzodiazepines, there was a 19 year gap before the introduction

More information

Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013

Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Michael Privitera, MD Professor of Neurology University of Cincinnati, Neuroscience Institute American Epilepsy Society Annual Meeting

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Newer drugs for epilepsy in children

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Newer drugs for epilepsy in children NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guidance 1.1 The newer antiepileptic drugs gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin (as an adjunctive therapy for partial

More information

Epilepsy and EEG in Clinical Practice

Epilepsy and EEG in Clinical Practice Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,

More information

Network meta-analysis of pharmacological interventions in the treatment of epilepsy

Network meta-analysis of pharmacological interventions in the treatment of epilepsy APPENDIX O Network meta-analysis of pharmacological interventions in the treatment of epilepsy 0 0. Introduction The results of conventional meta-analyses of direct evidence alone (as presented in the

More information

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic

More information

Epilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview

Epilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview : Clinical presentation and management Markus Reuber Professor of Clinical Neurology Academic Neurology Unit University of Sheffield, Royal Hallamshire Hospital. Is it epilepsy? Overview Common attack

More information

ORIGINAL CONTRIBUTION. Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy

ORIGINAL CONTRIBUTION. Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy ORIGINAL CONTRIBUTION Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy Hiba Arif, MD; Richard Buchsbaum; Joanna Pierro, BA; Michael Whalen, BA; Jessica Sims, MD; Stanley

More information

Choice of antie. which one to try fi rst an REVIEW

Choice of antie. which one to try fi rst an REVIEW 6 PRACTICAL NEUROLOGY REVIEW Choice of antie which one to try fi rst an Margaret J Jackson Consultant Neurologist, Department of Neurology, Royal Victoria Infi rmary, Newcastle upon Tyne, NE1 4LP; E-mail:

More information

p ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล

p ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล Natural Course and Prognosis of Epilepsy p ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล Introduction Prognosis of epilepsy generally means probability of being seizure-free after starting treatment

More information

A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine.

A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure (2005) 14, 117 122 www.elsevier.com/locate/yseiz A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine Ewa

More information

Epilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance

Epilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance Epilepsy: pharmacological treatment by seizure type Clinical audit tool Implementing NICE guidance 2012 NICE clinical guideline 137 Clinical audit tool: Epilepsy (2012) Page 1 of 25 This clinical audit

More information

Topics. What are Prediction Factors? Seizure type Etiologies Frequency of seizures Response to first AED Genetic?

Topics. What are Prediction Factors? Seizure type Etiologies Frequency of seizures Response to first AED Genetic? Early Recognition and Management of Refractory Epilepsy Topics How to predict who developed refractory epilepsy Associate Professor Somsak Tiamkao Division of Neurology, Department of Medicine Faculty

More information

For patients with epilepsy and the neurologists who treat them, the primary goal

For patients with epilepsy and the neurologists who treat them, the primary goal 38 Practical Neurology October 2008 A specialist answers the common question, My patient is seizure-free now what do I do? By Carl W. Bazil, MD, PhD For patients with epilepsy and the neurologists who

More information

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse Management of Epilepsy in Primary Care and the Community Carrie Burke, Epilepsy Specialist Nurse Epilepsy & Seizures Epilepsy is a common neurological disorder characterised by recurring seizures (NICE,

More information

The Effectiveness of Monotheraby in Epileptic Sudanese Patients

The Effectiveness of Monotheraby in Epileptic Sudanese Patients The Effectiveness of Monotheraby in Epileptic Sudanese Patients Amel Elmahi Mohamed (1) Sawsan A Aldeaf (1) Alsadig Gassoum (1) Alnada Abdalla Mohamed (2) Mohamed A Arbab (1,3) and Alamin Ebrahim (2) Abstract

More information

Medications for Epilepsy What I Need to Know

Medications for Epilepsy What I Need to Know Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for

More information

11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova

11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova EPILEPSY UPDATE Dr.Ram Sankaraneni Disclosures Speaker bureau LivaNova 1 Outline New onset Seizure Investigations in patients with epilepsy Medical management of epilepsy Non Pharmacological options in

More information

American Epilepsy Society Guidelines

American Epilepsy Society Guidelines Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy Report of the American Epilepsy Society and the Guideline Development, Dissemination,

More information

Epilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies

Epilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies Definitions Epilepsy Dr.Yotin Chinvarun M.D., Ph.D. Seizure: the clinical manifestation of an abnormal and excessive excitation of a population of cortical neurons Epilepsy: a tendency toward recurrent

More information

Monotherapy in Newly Diagnosed Epilepsy: Levetiracetam Versus Standard Anticonvulsants

Monotherapy in Newly Diagnosed Epilepsy: Levetiracetam Versus Standard Anticonvulsants Monotherapy in Newly Diagnosed Epilepsy: Levetiracetam Versus Standard Anticonvulsants Current Literature In Clinical Science KOMET: An Unblinded, Randomised, Two Parallel-Group, Stratified Trial Comparing

More information

The following information is based partially

The following information is based partially SELECTING APPROPRIATE PHARMACOTHERAPY FOR THE CHILD WITH EPILEPSY * Raman Sankar, MD, PhD ABSTRACT Selection of an antiepileptic drug (AED) for initial treatment of epilepsy in infancy, childhood, and

More information

Disclosure. Learning Objectives

Disclosure. Learning Objectives Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the

More information

A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults

A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults FORMULARY MANAGEMENT A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults NALIN PAYAKACHAT, MS; KENT H. SUMMERS, RPh, PhD; and JOHN P.

More information

Staging of Seizures According to Current Classification Systems December 10, 2013

Staging of Seizures According to Current Classification Systems December 10, 2013 Staging of Seizures According to Current Classification Systems December 10, 2013 Elinor Ben-Menachem, M.D.,Ph.D, Instituet of Clinical Neuroscience and Physiology, Sahlgren Academy, Goteborg University,

More information

EPILEPSY AFFECTS NEARLY 2 MILlion

EPILEPSY AFFECTS NEARLY 2 MILlion SCIENTIFIC REVIEW AND CLINICAL APPLICATIONS CLINICIAN S CORNER The New Antiepileptic Drugs Clinical Applications Suzette M. LaRoche, MD Sandra L. Helmers, MD EPILEPSY AFFECTS NEARLY 2 MILlion people in

More information

Levetiracetam monotherapy in juvenile myoclonic epilepsy

Levetiracetam monotherapy in juvenile myoclonic epilepsy Seizure (2008) 17, 64 68 www.elsevier.com/locate/yseiz Levetiracetam monotherapy in juvenile myoclonic epilepsy Deron V. Sharpe *, Anup D. Patel, Bassel Abou-Khalil, Gerald M. Fenichel Vanderbilt University

More information

Long-Term Efficacy and Safety of Zonisamide Monotherapy in Epilepsy Patients

Long-Term Efficacy and Safety of Zonisamide Monotherapy in Epilepsy Patients Journal of Clinical Neurology / Volume 3 / December, 2007 Original Articles Long-Term Efficacy and Safety of Zonisamide Monotherapy in Epilepsy Patients Sung-Pa Park, M.D., Sun-Young Kim, M.D., Yang-Ha

More information

On completion of this chapter you should be able to: list the most common types of childhood epilepsies and their symptoms

On completion of this chapter you should be able to: list the most common types of childhood epilepsies and their symptoms 9 Epilepsy The incidence of epilepsy is highest in the first two decades of life. It falls after that only to rise again in late life. Epilepsy is one of the most common chronic neurological condition

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable

More information

D espite recent developments in the nonmedical

D espite recent developments in the nonmedical 581 REVIEW New drugs for the treatment of epilepsy: a practical approach S Beyenburg, J Bauer, M Reuber... The availability of new antiepileptic drugs has broadened the spectrum of medical treatment options

More information

Abbreviated Update: Oral Anticonvulsants New Drug: ezogabine (Potiga)

Abbreviated Update: Oral Anticonvulsants New Drug: ezogabine (Potiga) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Low-Dose Topiramate Is Effective in the Treatment of Infantile Spasms

Low-Dose Topiramate Is Effective in the Treatment of Infantile Spasms Original Article 291 Low-Dose Topiramate Is Effective in the Treatment of Infantile Spasms Meng-Ying Hsieh, MD; Kuang-Lin Lin, MD; Huei-Shyong Wang, MD; Min-Liang Chou, MD; Po-Cheng Hung, MD; Ming-Yu Chang,

More information

PREVALENCE & TREATMENT OF PATIENTS WITH EPILEPSY ASSOCIATED WITH INTELLECTUAL DISABILITY: A PILOT STUDY IN PALESTINE

PREVALENCE & TREATMENT OF PATIENTS WITH EPILEPSY ASSOCIATED WITH INTELLECTUAL DISABILITY: A PILOT STUDY IN PALESTINE Vol.4, No., P.83-89, 006, ISSN 76-6807, http//www.iugzaza.edu.ps/ara/research/ PREVALENCE & TREATMENT OF PATIENTS WITH EPILEPSY ASSOCIATED WITH INTELLECTUAL DISABILITY: A PILOT STUDY IN PALESTINE Waleed

More information

Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management

Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management Current Neuropharmacology, 2009, 7, 77-82 77 Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management Erik K. St. Louis 1,*, William E. Rosenfeld 2 and Thomas Bramley 3 1 Mayo Clinic,

More information

Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain

Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain Vol. 25 No. 5S May 2003 Journal of Pain and Symptom Management S31 Neuropathic Pain: From Mechanisms to Treatment Strategies Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain Enrique

More information

THE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA

THE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA THE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA DR A.O. CHARWAY-FELLI, MD, PhD NEUROLOGIST 37 MILITARY HOSPITAL, ACCRA, GHANA SECRETARY-GENERAL AFRICAN ACADEMY OF NEUROLOGY

More information

The Epilepsy Prescriber s Guide to Antiepileptic Drugs

The Epilepsy Prescriber s Guide to Antiepileptic Drugs The Epilepsy Prescriber s Guide to Antiepileptic Drugs The Epilepsy Prescriber s Guide to Antiepileptic Drugs Philip N. Patsalos FRCPath, PhD Professor of Clinical Pharmacology and Consultant Clinical

More information

Epilepsies of Childhood: An Over-view of Treatment 2 nd October 2018

Epilepsies of Childhood: An Over-view of Treatment 2 nd October 2018 Epilepsies of Childhood: An Over-view of Treatment 2 nd October 2018 Dr Sophia Varadkar MRCPI, PhD Consultant Paediatric Neurologist and Honorary Senior Lecturer Great Ormond Street Hospital for Children

More information

ARTICLES Monotherapy in adults and elderly persons

ARTICLES Monotherapy in adults and elderly persons ARTICLES Monotherapy in adults and elderly persons Edward Faught, MD Address correspondence and reprint requests to Dr. Edward Faught, Department of Neurology, University of Alabama at Birmingham Epilepsy

More information

Disclosures. Objectives 2/16/2015. Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes

Disclosures. Objectives 2/16/2015. Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes 40 th Annual Progress in OBGYN February 19, 2015 Jennifer L. DeWolfe, DO Associate Professor UAB Epilepsy Center Director, BVAMC Sleep

More information

SELECTED POSTER PRESENTATIONS

SELECTED POSTER PRESENTATIONS POSTER PRESENTATIONS SELECTED POSTER PRESENTATIONS The following are summaries of posters presented at the 56th Annual Meeting of the American Epilepsy Society held in Seattle, Washington, December 6-11,

More information

An open label trial of topiramate as adjunctive therapy in Asian patients with refractory partial epilepsy

An open label trial of topiramate as adjunctive therapy in Asian patients with refractory partial epilepsy Neurol J Southeast Asia 2001; 6 : 121 127 An open label trial of topiramate as adjunctive therapy in Asian patients with refractory partial epilepsy 1 Shih Hui LIM, 2 Min Chun KWAN, 3 Margono Imam SJAHRIR,

More information

Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data

Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data Elmer ress Short Communication J Neurol Res. 2015;5(4-5):252-256 Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data

More information

Rohit R. Das, 1 David A. Griesemer, 2 and Sanjeev V. Kothare Introduction. 2. Methods

Rohit R. Das, 1 David A. Griesemer, 2 and Sanjeev V. Kothare Introduction. 2. Methods ISRN Neurology Volume 2013, Article ID 613456, 4 pages http://dx.doi.org/10.1155/2013/613456 Research Article The Role of Phenytoin in the Treatment of Localization Related Epilepsy: An International Internet-Based

More information

Lacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011

Lacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011 Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a

More information

Advances in the diagnosis and management of epilepsy in adults

Advances in the diagnosis and management of epilepsy in adults n DRUG REVIEW Advances in the diagnosis and management of epilepsy in adults Diego Kaski MRCP, PhD and Charles Cockerell MD, FRCP SPL This drug review looks at the key issues in diagnosing epilepsy, initiating

More information